Attached files
| file | filename |
|---|---|
| EX-10.23 - EXHIBIT 10.23 - FENNEC PHARMACEUTICALS INC. | v347891_ex10-23.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported) June 19, 2013
| Adherex Technologies Inc. |
| (Exact Name of Registrant as Specified in Its Charter) |
| Canada | 001-32295 | 20-0442384 | ||
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709
(Address of Principal Executive Offices) (Zip Code)
919-636-4530
(Registrant’s Telephone Number, Including Area Code)
Not applicable.
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Effective June 19, 2013, Dr. Thomas Spector resigned as Chief Scientific Officer of the Company, and entered into a Separation and Mutual Release Agreement with the Company, a copy of which is attached hereto as Exhibit 10.23. Dr. Spector will transition to a consultant to Adherex.
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
On June 18, 2013, Adherex Technologies Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:
1. The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:
| Name of Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||
| Robert C. Andrade | 25,157,326 | 535 | N/A | |||||||
| David Lieberman | 25,157,326 | 535 | N/A | |||||||
| Chris Rallis | 25,157,326 | 535 | N/A | |||||||
| Rostislav Raykov | 25,157,326 | 535 | N/A | |||||||
| Steven Skolsky | 25,157,326 | 535 | N/A | |||||||
2. The resolution to re-appoint Deloitte & Touche LLP as independent public accounting firm of the Company and to authorize the Audit Committee of the Board of Directors to fix their remuneration was approved based on the following vote:
| Votes For | 25,157,799 | |||
| Votes Withheld | 62 | |||
| Abstentions | 0 | |||
| Broker Non-Votes | Not Applicable |
3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:
| Votes For | 25,123,416 | |||
| Votes Withheld | 34,445 | |||
| Abstentions | 0 | |||
| Broker Non-Votes | Not Applicable |
4. The resolution to vote on the frequency of voting on executive compensation was approved for 1 Year based on the following vote:
| 1 Year | 25,156,697 | |||
| 2 Years | 1,111 | |||
| 3 Years | 53 | |||
| Withhold | 588 |
5. The resolution to vote on the approval of the Corporation’s stock option plan and the unallocated stock options thereunder was approved based on the following vote:
| For | 25,094,603 | |||
| Against | 63,798 | |||
| Withold | 0 |
| Exhibit | ||
| 10.23 | Separation and Mutual Release Agreement by and between Adherex Technologies, Inc. and Dr. Thomas Spector |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: June 19, 2013 | Adherex Technologies Inc. | ||
| By: | /s/ Robert Andrade | ||
| Chief Financial Officer | |||